Stock Groups

Mixed COVID vaccine schedules offer stronger boost after Sinovac regimen

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – CoronaVac vaccine from Chinese Sinovac against coronavirus (COVID-19), pictured in the recently inaugurated production laboratory that will manufacture the vaccine. Constantine, Algeria, September 29th, 2021. REUTERS/Ramzi Boudina

(Reuters) – Giving COVID-19 vaccines from either AstraZeneca-Oxford, Pfizer-BioNTech or Johnson & Johnson (NYSE:) as a booster after two doses of the COVID-19 inactivated-virus vaccine from Sinovac, leads to significantly higher antibodies, a study has found.

Oxford University researchers said that the best results were obtained when an RNA vaccination was used as a booster for Sinovac’s CoronaVac.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]